Enterprise Aarkstore – innovation in drug delivery. Oral Solid: Aarkstore – Market Research Enterprise.

Innovation in delivery. Oral Solid drugs: advances in nanotechnology. Send recipes and control peptide.

Contents:.

Innovation in the delivery of solid oral drug.
18 Executive Summary.
Market. 18 dynamics and trends.
Advancement of nanotechnology. 19.
Innovation and change in injectables. Shipping Pak 20.
Progress and delays in the export control 21.
Advances in oral prodrug delivery. 22.
Advances in taste masking. 23 technology.
24 innovative companies.
Chapter 1: Market Dynamics and Trends. 28.
Summary 28.
Market 29.
31 dynamic markets.
33 key indicators.
38 Trends.
Nanomedicine 38.
The change from 39 injectables.
Prodrugs 40.
Release Chrono 41.
ODT 41.
OSF 42.
42 on scholarship.
Poor patients. 42.
42 Injections.
absorbption Fair 42.
Children 43.
43 elderly.
Solubility and absorption parameters. 43.
Reduced side effects profile. 44.
Send this protein does not offend 45.
Change from injectables route to oral drug delivery. 45.
Directed and send shipments to reduce delays. Side effects that may occur. 46.
Technology recipe for low solubility compounds. 46.
Covers 47 delicious recipes for children and the elderly.
48 landscape competition
Conclusion And 50 the key
Chapter 2, advances in nanotechnology. 56.
Summary 56.
Introduction 57.
Nanotechnology platforms for drug delivery to the oral 59.
Self – Emulsifying System Release Tablet (secret) 59.
Technology. 59.
Application 59.
Technology nanomedicine Biotransport 60.
Technology. 60.
Application 60.
Nanobodies 61.
Technology 61.
Application 61.
Nano. NanoDel 62.
Technology 62.
Application 62.
gpMask P – 63.
Technology. 63.
Application 64.
NanoDRY and NanoCOAT 64.
Technology 64.
Application 64.
Solumer 67.
Technology 67.
Application 67.
Nanocells 69.
Technology. 69.
Application 70.
Polymer systems Nano Delivery (PNDS) 70.
Technology. 70.
Application 71.
FluidCrystal NP Oral 71 nm.
Technology 71.
Application. 72.
Cap and technology BioOral 72.
Technology. 72.
Application 73.
Nab technology and 73 Protospheres.
Technology 73.
Application 73.
Technology. NanoCrystal 74.
Technology 74.
Application 74.
Bioral 75.
Technology. 75.
Application 75.
Nano Squalenoyl 76.
NanoMega 76.
Nod drug 76.
Chapter 3: Innovation in the transition to submit oral injectables. 80.
Summary 80.
Introduction 81.
Drivers. 81.
Accepted by patients, and 81.
81 cost.
Response 82.
Progress in delivering the injection. 82.
The challenge of delivering oral drug 83.
Technology used in oral drug delivery of peptides and proteins. 84.
84 inhibitory activity.
85 increase the permeability.
Mucoadhesives 85.
85 Technology Encapsulation.
M cell targeting. 86.
86 competitive landscape.
Osteoporosis and other bone. 88 other related conditions.
Calcitonin 88.
Maintain and improve current marketing landscape. 89.
Oral product development in 1991.
Para 94 hormone
Maintain and improve current marketing landscape. 94.
Oral product development in 1996.
and 97 with oral calcitonin to PTH.
Bisphosphonates 97.
Current treatment. Designs and markets in 1997.
New products in the oral cavity. 99 development.
Disease and diabetes. Other metabolic 104.
Insulin Oral 104.
Drug Oramed 104.
Biocon. Ltd 105.
Emisphere Technologies 105.
Diabetology 106.
106 drug nod
107 Drug Access.
NanoMega Corporation 107 physicians.
Inc Biodel 108.
Drug May Ltd 108.
Glucagon – like peptide – 1 (GLP – 1) and GLP – 1 analogs 108.
Oral GLP – 1 and GLP – 1 analogs 110.
Obesity. 114.
Degeneration and other 115 CNS.
Oligotropin. 115.
Endometriosis. And prostate cancer. 115.
Leuprolide 115.
116 heart and blood vessels.
116 analogs Angiotensin.
Innovative methods of vaccine development. 118.
Mucosis BV 119.
Technology Plug – and Play – 119.
GEM particles. 119.
Mimopath 119.
Pty Ltd Ondek 120.
Helicobacter pylori Platform Technology (HPPT) 120.
Infexion 121.
Kancer 121.
121 Solutions immunity
Liporale 122.
Chapter 4 advances and delays in the export control 124.
Summary 124.
Introduction 125.
Type of control 125 release system.
Sustainability 125 release.
Leave Pulsatile 125.
Drug delivery Modified 126.
Technology. disintegrating Fast 126.
Baby formula – ODT 126.
Schizophrenia And disorder bipolar – ODT 127.
Alzheimer's disease – ODT 128.
Parkinson's disease – ODT 129.
And anxiety disorders watch – ODT 129.
Major depression – ODT 130.
Nausea and vomiting – ODT 131.
Migraine. – ODT 131.
Autistic – ODT 132.
GERD and gastroparesis – ODT 133.
Release 135 control mechanisms.
Zero 135 order
Heart failure and hypertension. – Release 135.
Pain – Liberation 138.
ADHD – Liberation 141.
Multiple sclerosis – discharge 141.
Muscle relaxation – release. 142.
Parkinson's disease – release. 144.
The Depression – sustainability. 144.
Binary 147.
Diabetes type 2 – GDP. 147.
High blood pressure – 149 GDP.
Other 150.
Biphasic 150 drug release.
Asthma – biphasic 151 release
Pain – release biphasic 151.
ADHD – let biphasic 152.
Hypertension. – Leave biphasic 152.
Position 153.
Parkinson's disease. – Letting go of biphasic 154.
Insomnia – left dormant. biphasic 155.
Spasticity – letting go of biphasic 156.
GERD – position 156 release
Diabetes type. 2 – Position release extended 157.
Flashing Hot – position extended release 157.
Pain – location release extended 158.
GERD – position release extended 158.
Parkinson's disease – position release extended 158.
159 other
Intensive 159.
Be over 159.
Pulse Multiple 160.
Targeted delivery. 160 colon.
Ulcerative inflammation, stomach and intestinal inflammation. – Left colon targeted 161.
Nutraceutical – left colon targeted 162.
Colorectal polysaccharide selective 163.
Technology. COLAL 163.
Leave Chrono 164.
rheumatoid arthritis – release Chrono 165.
Severe asthma. – Leave Chrono 166.
rheumatica Polymyalgia – release Chrono 166.
Release Insomnia – Chrono 166.
167 Formula Sublingual.
Recipe for fighting drug addiction or psychostimulant 167 violations.
Run – Lock 168.
OraGuard 169.
NanoDRY and NanoCOAT 170.
ORADUR 170.
Technology hatred 171.
ADPREM Egalet 172.
DETERx 173.
Avoid 174.
174 strategic alliances.
Chapter 5 advances in the delivery. oral prodrug 178.
178 Summary.
Introduction 179.
By converting its site work. 181.
By linking the chemical or promoiety provider / attachment to.
Drug use 182.
By defects in the active drug. 183.
By service provider link or category bioprecursor 183.
Applications of Technology prodrug 185.
Reduce the side effects profile. 185.
specificity Intelligence – 185 colon.
Program covers Taste 186.
Product markets and market share. 186.
Virus prodrugs 186.
oseltamivir 186.
Valaciclovir 187.
Valganciclovir 189.
Famciclovir 190.
Anticancer prodrugs. 191.
TS – 1 192.
prodrugs heart 194.
194 ACE inhibitors.
Angiotensin II receptor 194 against.
HMG Co 195 reductase inhibitors.
Respiratory prodrugs 195.
Bambuterol 195.
CNS prodrugs 195.
Lisdexamfetamine 195.
Process development and early delayed. Formula 197 products.
Oral Bioavailability improvement. Reducing the toxicity of the drug injection market, old 197.
Virus prodrugs 197.
Cidofovir 197.
Vidarabine 200.
200 Zanamivir.
Anticancer prodrugs 201.
Triciribine 201.
Camptothecin 202.
Gemcitabine 204.
Docetaxel 206.
Methotrexate 208.
Aimpila 210.
FAP enabled smart special agent poisoning. prodrug 211.

For more information please contact
http://www.aarkstore.com/reports/Innovations-in-Oral-Solid-Drug-Delivery-Advances-in-nanotechnology-controlled-formulations-peptide-delivery-45545.html.

About the Author

Minal H
SEO
vinod.minal@gmail.com
http://www.aarkstore.com

MEDICAL MARIJUANA EVALUATIONS AVAILABLE FOR $125